ARS Pharmaceuticals (SPRY) announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for EURneffy for the emergency treatment of allergic reactions in adults and children who weigh greater than 30 kg.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY: